Adjuvant systemic therapies in women with breast cancer:an audit of clinical practice in Italy
F. Roila(University of Perugia), Aron Goldhirsch(Istituti di Ricovero e Cura a Carattere Scientifico), Andrea Veronesi(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), L. Patoia(University of Perugia), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Enzo Ballatori(University of L'Aquila), Saverio Cinieri(Ospedale A. Perrino), S. Palazzo(Azienda Ospedaliera di Cosenza), Gian Luigi Cetto
Cited by 32
Related Papers
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
|Annals of Oncology|2013|3.7k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
|The Lancet|2007|1.5k
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
|New England Journal of Medicine|2014|751
Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update
|Journal of Clinical Oncology|2006|725